ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

C4XD C4x Discovery Holdings Plc

12.00
0.00 (0.00%)
01 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
C4x Discovery Holdings Plc LSE:C4XD London Ordinary Share GB00BQQ2RV18 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 12.00 10.30 10.80 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 1.71M -11.11M -0.0441 -2.72 30.27M
C4x Discovery Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker C4XD. The last closing price for C4x Discovery was 12p. Over the last year, C4x Discovery shares have traded in a share price range of 7.30p to 21.90p.

C4x Discovery currently has 252,227,097 shares in issue. The market capitalisation of C4x Discovery is £30.27 million. C4x Discovery has a price to earnings ratio (PE ratio) of -2.72.

C4x Discovery Share Discussion Threads

Showing 2926 to 2946 of 3150 messages
Chat Pages: 126  125  124  123  122  121  120  119  118  117  116  115  Older
DateSubjectAuthorDiscuss
03/1/2024
09:39
thanks - aconic - I only picked this up from RNS this morning but looks very overlooked at £30m market cap.
nigelpm
03/1/2024
09:35
Runway was already to Dec 24 and now extended to around Sept 2025, even without any further milestone payments or a sale of the non-core Malt-1 asset (both of which are expected).

Mcap now 30m. Morphic whose only asset is in the same space as ONE of C4XD's (and looking inferior in phase 1 trials due to the worryingly high dose required) has a market cap of $1.44 billion.

This has been floating under the radar for far too long.

Firestarter clearly short and desperately hoping to close the position at less of a loss.

All (unwarranted) funding worries now pushed out to rediculous time horizons and CD has already said that it's entirely possible that the company is now self financing. There's really no reason for this not to fly much higher after the initial wave of profit taking.

1aconic
03/1/2024
09:13
10p by close
firestarter1
03/1/2024
09:13
I asume C4X may pay a great dividend in the future.
luckyabbeygale
03/1/2024
09:07
Many spiked in over 14p Now time to dive to 10
firestarter1
03/1/2024
09:02
Nigel,

Firestarter does this on so many shares in the news......all BS of course, best ignored. He will go plague another share tomorrow.

intoodeep
03/1/2024
09:01
HZM VAST and this one are the best to be in.
luckyabbeygale
03/1/2024
09:01
Shorts increased by 6% Hence why it is not risingIf shorts were closing there would be more buying
firestarter1
03/1/2024
09:00
Looking weak and nt to sell
firestarter1
03/1/2024
08:55
Firestarter filtered - absolute nutcase.
nigelpm
03/1/2024
08:54
Firestarter who do you work for?
intoodeep
03/1/2024
08:48
Time to add. Buyers was paying 15p first thing.
luckyabbeygale
03/1/2024
08:46
In for some more at 12.7p.
luckyabbeygale
03/1/2024
08:46
No one talking bout it wirher
firestarter1
03/1/2024
08:46
Notninterest
firestarter1
03/1/2024
08:45
All folks spiked in
firestarter1
03/1/2024
08:45
Dumping hard
firestarter1
03/1/2024
08:45
22million mkt cap according to advfn
p@
03/1/2024
08:42
Wow - incredible stuff here - market cap of £32m but c. £20m in bank with no debt and many opportunities to generate cash.
nigelpm
03/1/2024
08:42
Drug discovery company C4X Discovery said it has received a milestone payment of USD11 million from FTSE 100-listed pharmaceutical firm AstraZeneca, triggered by pre-clinical progress of C4X Discovery's NFT2 Activator programme. AstraZeneca is developing C4X Discovery's former programme to deliver an oral therapy for the treatment of inflammatory and respiratory diseases, with a lead focus on chronic respiratory disease. As announced under the terms of the licencing agreement in November 2022, C4X Discovery received an initial USD2 million upfront payment from AstraZeneca and is potentially entitled to receive up to USD400 million in preclinical, clinical development and commercial milestones, as well as tiered mid-single digit royalties on future sales. C4X Discovery Clive Dix commented: "This significant preclinical milestone payment marks the progress AstraZeneca has made in driving the NRF2 Activator programme forward. NRF2 is a challenging target and this achievement provides further validation of our ability to generate differentiated, quality molecules in immuno-inflammation."
p@
03/1/2024
08:36
Good morning

All UK shares investing seems risky at present certainly those on AIM but I'm in at 12p
DYOR!

maytrees
Chat Pages: 126  125  124  123  122  121  120  119  118  117  116  115  Older

Your Recent History

Delayed Upgrade Clock